Use of large combinational chemical libraries for anticancer drug discovery

S. E. Salmon, Kit Lam, S. Felder, H. Yeoman, J. Schlessinger, A. Ullrich, V. Krchnak, M. Lebl

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A new technology for drug discovery (Selectide technology) has been developed which greatly extends the capability for rapid molecular and cellular screening to large libraries containing millions of chemically synthesized compounds. Using a split synthesis approach to condensation chemistry, we recognized that each individual compound of potential interest is located on a different solid phase resin bead. Screening for binding activity on the bead surface: In order to screen for biological activity, we used several cleavable linkers which could release a portion of the compound from each bead into the solution phase in each of two sequential steps. For libraries comprised of peptides, there is sufficient residual peptide on each bead to permit sequence determination via Edman degradation. For non-peptide libraries, a system of peptide encoding is used on each bead so that the structure of the non-peptide compound can be determined by decoding the information conveyed by the peptide (which can be sequenced). We have applied this technology to various areas of drug discovery including a major interest in the development of anticancer drugs. Molecular targets under evaluation include cell surface monoclonal immunoglobulin on B-cell lymphomas, the epidermal growth factor receptor, and the HER2-neu receptor. Solution phase screening with releasable libraries is being used to evaluate anti-tumor activity using a battery of human tumor cell lines. Based on data obtained thus far, we believe that the Selectide technology has the potential for discovering novel new anticancer drugs.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalInternational Journal of Pharmacognosy
Volume33
Issue numberSUPPL.
StatePublished - 1995
Externally publishedYes

Fingerprint

Small Molecule Libraries
Drug Discovery
Libraries
Technology
Peptides
Peptide Library
B-Cell Antigen Receptors
B-Cell Lymphoma
Tumor Cell Line
Pharmaceutical Preparations
Sequence Analysis
Neoplasms

Keywords

  • Cancer screening
  • Combinatorial chemistry
  • Drug discovery
  • Peptides

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Salmon, S. E., Lam, K., Felder, S., Yeoman, H., Schlessinger, J., Ullrich, A., ... Lebl, M. (1995). Use of large combinational chemical libraries for anticancer drug discovery. International Journal of Pharmacognosy, 33(SUPPL.), 67-74.

Use of large combinational chemical libraries for anticancer drug discovery. / Salmon, S. E.; Lam, Kit; Felder, S.; Yeoman, H.; Schlessinger, J.; Ullrich, A.; Krchnak, V.; Lebl, M.

In: International Journal of Pharmacognosy, Vol. 33, No. SUPPL., 1995, p. 67-74.

Research output: Contribution to journalArticle

Salmon, SE, Lam, K, Felder, S, Yeoman, H, Schlessinger, J, Ullrich, A, Krchnak, V & Lebl, M 1995, 'Use of large combinational chemical libraries for anticancer drug discovery', International Journal of Pharmacognosy, vol. 33, no. SUPPL., pp. 67-74.
Salmon SE, Lam K, Felder S, Yeoman H, Schlessinger J, Ullrich A et al. Use of large combinational chemical libraries for anticancer drug discovery. International Journal of Pharmacognosy. 1995;33(SUPPL.):67-74.
Salmon, S. E. ; Lam, Kit ; Felder, S. ; Yeoman, H. ; Schlessinger, J. ; Ullrich, A. ; Krchnak, V. ; Lebl, M. / Use of large combinational chemical libraries for anticancer drug discovery. In: International Journal of Pharmacognosy. 1995 ; Vol. 33, No. SUPPL. pp. 67-74.
@article{5399fe0fe6b94172a7df78f656b9c557,
title = "Use of large combinational chemical libraries for anticancer drug discovery",
abstract = "A new technology for drug discovery (Selectide technology) has been developed which greatly extends the capability for rapid molecular and cellular screening to large libraries containing millions of chemically synthesized compounds. Using a split synthesis approach to condensation chemistry, we recognized that each individual compound of potential interest is located on a different solid phase resin bead. Screening for binding activity on the bead surface: In order to screen for biological activity, we used several cleavable linkers which could release a portion of the compound from each bead into the solution phase in each of two sequential steps. For libraries comprised of peptides, there is sufficient residual peptide on each bead to permit sequence determination via Edman degradation. For non-peptide libraries, a system of peptide encoding is used on each bead so that the structure of the non-peptide compound can be determined by decoding the information conveyed by the peptide (which can be sequenced). We have applied this technology to various areas of drug discovery including a major interest in the development of anticancer drugs. Molecular targets under evaluation include cell surface monoclonal immunoglobulin on B-cell lymphomas, the epidermal growth factor receptor, and the HER2-neu receptor. Solution phase screening with releasable libraries is being used to evaluate anti-tumor activity using a battery of human tumor cell lines. Based on data obtained thus far, we believe that the Selectide technology has the potential for discovering novel new anticancer drugs.",
keywords = "Cancer screening, Combinatorial chemistry, Drug discovery, Peptides",
author = "Salmon, {S. E.} and Kit Lam and S. Felder and H. Yeoman and J. Schlessinger and A. Ullrich and V. Krchnak and M. Lebl",
year = "1995",
language = "English (US)",
volume = "33",
pages = "67--74",
journal = "Pharmaceutical Biology",
issn = "1388-0209",
publisher = "Informa Healthcare",
number = "SUPPL.",

}

TY - JOUR

T1 - Use of large combinational chemical libraries for anticancer drug discovery

AU - Salmon, S. E.

AU - Lam, Kit

AU - Felder, S.

AU - Yeoman, H.

AU - Schlessinger, J.

AU - Ullrich, A.

AU - Krchnak, V.

AU - Lebl, M.

PY - 1995

Y1 - 1995

N2 - A new technology for drug discovery (Selectide technology) has been developed which greatly extends the capability for rapid molecular and cellular screening to large libraries containing millions of chemically synthesized compounds. Using a split synthesis approach to condensation chemistry, we recognized that each individual compound of potential interest is located on a different solid phase resin bead. Screening for binding activity on the bead surface: In order to screen for biological activity, we used several cleavable linkers which could release a portion of the compound from each bead into the solution phase in each of two sequential steps. For libraries comprised of peptides, there is sufficient residual peptide on each bead to permit sequence determination via Edman degradation. For non-peptide libraries, a system of peptide encoding is used on each bead so that the structure of the non-peptide compound can be determined by decoding the information conveyed by the peptide (which can be sequenced). We have applied this technology to various areas of drug discovery including a major interest in the development of anticancer drugs. Molecular targets under evaluation include cell surface monoclonal immunoglobulin on B-cell lymphomas, the epidermal growth factor receptor, and the HER2-neu receptor. Solution phase screening with releasable libraries is being used to evaluate anti-tumor activity using a battery of human tumor cell lines. Based on data obtained thus far, we believe that the Selectide technology has the potential for discovering novel new anticancer drugs.

AB - A new technology for drug discovery (Selectide technology) has been developed which greatly extends the capability for rapid molecular and cellular screening to large libraries containing millions of chemically synthesized compounds. Using a split synthesis approach to condensation chemistry, we recognized that each individual compound of potential interest is located on a different solid phase resin bead. Screening for binding activity on the bead surface: In order to screen for biological activity, we used several cleavable linkers which could release a portion of the compound from each bead into the solution phase in each of two sequential steps. For libraries comprised of peptides, there is sufficient residual peptide on each bead to permit sequence determination via Edman degradation. For non-peptide libraries, a system of peptide encoding is used on each bead so that the structure of the non-peptide compound can be determined by decoding the information conveyed by the peptide (which can be sequenced). We have applied this technology to various areas of drug discovery including a major interest in the development of anticancer drugs. Molecular targets under evaluation include cell surface monoclonal immunoglobulin on B-cell lymphomas, the epidermal growth factor receptor, and the HER2-neu receptor. Solution phase screening with releasable libraries is being used to evaluate anti-tumor activity using a battery of human tumor cell lines. Based on data obtained thus far, we believe that the Selectide technology has the potential for discovering novel new anticancer drugs.

KW - Cancer screening

KW - Combinatorial chemistry

KW - Drug discovery

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=0028804322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028804322&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028804322

VL - 33

SP - 67

EP - 74

JO - Pharmaceutical Biology

JF - Pharmaceutical Biology

SN - 1388-0209

IS - SUPPL.

ER -